



Issues and Events

UPDATES TO THE STANDARDS OF MEDICAL CARE IN DIABETES—2021

The American Diabetes Association issued important updates to the 2021 Standards of Medical Care in Diabetes (Standards of Care). Changes include new data on teplizumab and SGLT2 inhibitors as well as medications' effects on patients with chronic kidney disease. Updated sections include Classification and Diagnosis of Diabetes, Cardiovascular Disease and Risk Management, and Microvascular Complications and Foot Care. Access the Standards of Care as well as all updates at care.diabetesjournals.org/content/44/Supplement_1.

IDF VIRTUAL CONGRESS 2021

The International Diabetes Federation (IDF) Congress 2021 will be held virtually on 6–11 December 2021. The program includes updates on the latest research and tools to manage and prevent diabetes complications and is organized across four streams—Cardiovascular Disease and Hypertension, Eye and Kidney, Foot and Neuropathy, and COVID-19 and Diabetes. Registration and abstract submission are open. For further information, visit <https://idf2021.org>.

CONSENSUS REPORT: MANAGEMENT OF TYPE 1 DIABETES IN ADULTS

The first consensus report on the management of type 1 diabetes in adults by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) has been copublished in *Diabetes Care* and *Diabetologia*. The report addresses diagnosis, aims of management, schedule of care, diabetes self-management education and support, glucose monitoring, insulin therapy, hypoglycemia, behavioral considerations, psychosocial care, diabetic ketoacidosis, pancreas and islet transplantation, adjunctive therapies, special populations, inpatient management, and future perspectives. Read the full consensus report online at <https://doi.org/10.2337/dci21-0043>.

SPECIAL PODCAST EPISODE: SGLT2 INHIBITORS AND DIABETIC KIDNEY DISEASE

This special episode of *Diabetes Core Update*, made possible

by an unrestricted educational grant from AstraZeneca, explores beneficial effects of SGLT2 inhibitors on kidney function. SGLT2 inhibitors are a class of medication used to help lower blood glucose levels in people with type 2 diabetes, but recent trials have shown that SGLT2 inhibitors can also help slow the progression of diabetic kidney disease and chronic kidney disease. Drs. Neil Skolnik and John Russell discuss these trials, the exciting data showing the beneficial effects of SGLT2 inhibitors on diabetic kidney disease, recommendations for screening for and diagnosing kidney disease in people with diabetes, and strategies for educating patients about renal disease. To listen to the episode, visit <https://www.diabetesjournals.org/content/sglt2i-dkd>.

COMPENDIUM: CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES

ADA's most recently published clinical compendium discusses diabetic kidney disease, mechanisms underlying progression to diabetic vascular disease, and opportunities to improve clinical outcomes. This monograph is supported by unrestricted education grants from AstraZeneca and Bayer. To access this and other clinical compendia for free, visit professional.diabetes.org/monographs.

"DIABETES AND COVID-19" SPECIAL ARTICLE COLLECTIONS

These online collections of articles feature the latest studies, clinical observations, and commentary published in *Diabetes Care* and *Diabetes* on COVID-19 and diabetes. Topics include management of diabetes and its complications during the pandemic, blood glucose control and remote glucose monitoring, and outcomes in patients with hyperglycemia, cardiovascular risk, and obesity. The special article collections are updated regularly as relevant articles are published online. To access the *Diabetes Care* collection, visit care.diabetesjournals.org/collection/diabetes-and-COVID19. For the *Diabetes* collection, visit diabetes.diabetesjournals.org/collection/diabetes-and-COVID19-articles.

Diabetes Care (print ISSN 0149-5992, online ISSN 1935-5548) is owned, controlled, and published monthly by the American Diabetes Association, Inc., 2451 Crystal Drive, Suite 900, Arlington, VA 22202. *Diabetes Care* is a registered trademark of the American Diabetes Association. **Periodicals postage** paid at Arlington, VA, and additional mailing offices. **POSTMASTER:** Send all UAA to CFS (see DMM 507.1.5.2). **NON-POSTAL AND MILITARY FACILITIES:** Send address corrections to American Diabetes Association, Membership & Publication Operations, PO Box 37433, Boone, IA 50037-0433. Claims for missing issues should be made within 6 months of publication. The publisher expects to supply missing issues free of charge only when losses have been sustained in transit and when the reserve stock permits.